R916562

Cat. No.:	HY-104075
CAS No.:	1037798-41-6
Molecular Formula:	$C_{26}H_{30}ClN_9S$
Molecular Weight:	536.09
Target:	TAM Receptor; VEGFR
Pathway:	Protein Tyrosine Kinase/RTK
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	R916562 is an orally active and selective Axl/VEGF-R2 inhibitor with IC_{50}s of 136 nM and 24 nM, respectively. R916562 has anti-angiogenesis and anti-metastasis[1].	
IC_{50} & Target	Axl 136 nM (IC_{50})	VEGF-R2 24 nM (IC_{50})
In Vivo	R916562 treatment at 85 mg/kg or 125 mg/kg orally b.i. d for 21 days results in statistically significant tumor growth inhibitions of 69% or 83% respectively. R916562 shows 73% reduction in fibroblast growth factor-induced neovascularization in a mouse corneal micropocket assay at a dose of 100 mg/kg and 50% reduction at 50 mg/kg[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.	

PROTOCOL

Animal Administration [1]	Mice[1] The nu/nu mice are used in the study. In the MDA-MB-231 human breast cancer xenograft model, mice are given 125 mg/kg b.i.d. orally for 21 days. Mean tumor volume is measured[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Goff D, et al. Discovery of dual Axl/VEGF-R2 inhibitors as potential anti-angiogenic and anti-metastatic drugs for cancer chemotherapy. Bioorg Med Chem Lett. 2017 Aug 15; 27(16):3766-3771.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA